Conning Inc. Bristol Myers Squibb CO Transaction History

Conning Inc.

$2.89 Billion
Q3 2024

A detailed history of Conning Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Conning Inc. holds 761,123 shares of BMY stock, worth $43.9 Million. This represents 1.37% of its overall portfolio holdings.

Number of Shares

761,123

Previous 855,035 10.98%

Holding current value

$43.9 Million

Previous $35.5 Million 10.92%

% of portfolio

1.37%

Previous 1.33%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	SELL	$39.66 - $51.75 $3.72 Million - $4.86 Million	-93,912 Reduced 10.98%	761,123 $39.4 Million
Q2 2024 Jul 26, 2024	BUY	$40.25 - $52.99 $4.93 Million - $6.49 Million	122,405 Added 16.71%	855,035 $35.5 Million
Q1 2024 Apr 26, 2024	BUY	$47.98 - $54.4 $2.71 Million - $3.08 Million	56,543 Added 8.36%	732,630 $39.7 Million
Q4 2023 Jan 29, 2024	BUY	$48.48 - $57.85 $3.9 Million - $4.65 Million	80,386 Added 13.49%	676,087 $34.7 Million
Q3 2023 Oct 26, 2023	BUY	$57.89 - $64.73 $2.34 Million - $2.61 Million	40,340 Added 7.26%	595,701 $34.6 Million
Q2 2023 Jul 21, 2023	BUY	$63.71 - $70.74 $696,286 - $773,117	10,929 Added 2.01%	555,361 $35.5 Million
Q1 2023 Apr 27, 2023	BUY	$65.71 - $74.53 $4.1 Million - $4.65 Million	62,324 Added 12.93%	544,432 $37.7 Million
Q4 2022 Feb 07, 2023	SELL	$68.48 - $81.09 $3.93 Million - $4.66 Million	-57,435 Reduced 10.65%	482,108 $34.7 Million
Q3 2022 Oct 28, 2022	SELL	$0.13 - $76.84 $8,244 - $4.87 Million	-63,418 Reduced 10.52%	539,543 $38.3 Million
Q2 2022 Jul 20, 2022	SELL	$72.62 - $79.98 $4.73 Million - $5.21 Million	-65,135 Reduced 9.75%	602,961 $46.4 Million
Q1 2022 May 02, 2022	SELL	$61.48 - $73.72 $14.3 Million - $17.2 Million	-233,159 Reduced 25.87%	668,096 $48.8 Million
Q4 2021 Jan 27, 2022	BUY	$53.63 - $62.52 $6.9 Million - $8.05 Million	128,697 Added 16.66%	901,255 $56.2 Million
Q3 2021 Nov 05, 2021	SELL	$59.17 - $69.31 $1.31 Million - $1.54 Million	-22,210 Reduced 2.79%	772,558 $45.7 Million
Q2 2021 Jul 29, 2021	SELL	$61.91 - $67.42 $615,694 - $670,491	-9,945 Reduced 1.24%	794,768 $53.1 Million
Q1 2021 Apr 23, 2021	BUY	$59.34 - $66.74 $1.91 Million - $2.14 Million	32,133 Added 4.16%	804,713 $50.8 Million
Q4 2020 Jan 28, 2021	BUY	$57.74 - $65.43 $2.3 Million - $2.6 Million	39,811 Added 5.43%	772,580 $47.9 Million
Q3 2020 Oct 21, 2020	BUY	$57.43 - $63.64 $450,423 - $499,128	7,843 Added 1.08%	732,769 $44.2 Million
Q2 2020 Aug 07, 2020	SELL	$54.82 - $64.09 $1.08 Million - $1.26 Million	-19,654 Reduced 2.64%	724,926 $42.6 Million
Q1 2020 Apr 29, 2020	BUY	$46.4 - $67.43 $32.6 Million - $47.4 Million	702,269 Added 1659.78%	744,580 $41.5 Million
Q4 2019 Jan 29, 2020	BUY	$49.21 - $64.19 $773,433 - $1.01 Million	15,717 Added 59.1%	42,311 $2.72 Million
Q3 2019 Oct 30, 2019	SELL	$42.77 - $50.71 $3,378 - $4,006	-79 Reduced 0.3%	26,594 $1.35 Million
Q2 2019 Jul 25, 2019	SELL	$44.62 - $49.34 $399,259 - $441,494	-8,948 Reduced 25.12%	26,673 $1.21 Million
Q1 2019 Apr 22, 2019	SELL	$45.12 - $53.8 $3,609 - $4,304	-80 Reduced 0.22%	35,621 $1.7 Million
Q4 2018 Jan 29, 2019	SELL	$48.76 - $63.23 $155,544 - $201,703	-3,190 Reduced 8.2%	35,701 $1.86 Million
Q3 2018 Oct 26, 2018	SELL	$55.19 - $62.25 $3.8 Million - $4.29 Million	-68,878 Reduced 63.91%	38,891 $2.41 Million
Q2 2018 Jul 25, 2018	SELL	$50.53 - $62.98 $21.6 Million - $26.9 Million	-427,196 Reduced 79.85%	107,769 $5.96 Million
Q1 2018 May 04, 2018	BUY	$59.92 - $68.98 $3.66 Million - $4.21 Million	61,051 Added 12.88%	534,965 $33.8 Million
Q4 2017 Jan 30, 2018	SELL	$59.94 - $65.35 $453,985 - $494,960	-7,574 Reduced 1.57%	473,914 $29 Million
Q3 2017 Oct 20, 2017	BUY	$55.23 - $63.74 $26.6 Million - $30.7 Million	481,488	481,488 $30.7 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Conning Inc., based on Form 13F filings with the SEC.

News

Stay updated on Conning Inc. with notifications on news.

Account